m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00544)
| Name |
Imatinib mesylate
|
||||
|---|---|---|---|---|---|
| Synonyms |
Imatinib; Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; Imatinib(STI571); Gleevec; Glivec; Imatinib (mesylate); Imatinib Mesylate (STI571); Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (USAN); Imatinib mesylate, 98%; Imatinib, methanesulfonate salt; ST-1571 Mesylate; imatinib methanesulfonate; imatinib monomesylate; 220127-57-1; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate; 8A1O1M485B; AK-44930; CGP-57148B; CHEBI:31690; HSDB 7142; NSC-716051; UNII-8A1O1M485B; STI571; 152459-95-5; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; CCRIS 9076; CGP-57148; CHEMBL941; Cgp 57148; N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; BKJ8M8G5HI; UNII-BKJ8M8G5HI
Click to Show/Hide
|
||||
| Status |
Approved
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C30H35N7O4S
|
||||
| InChI |
1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
|
||||
| InChIKey |
YLMAHDNUQAMNNX-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| INTEDE Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
YTH domain-containing protein 2 (YTHDC2)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [1], [2] | ||
References